Nestlé Health Science Refocuses As It Drops Peanut Allergy Treatment
Executive Summary
VMS, active nutrition and medical nutrition will be Nestle Health Science's main focus areas going forward with the business looking to offload peanut allergy treatment Palforzia. The Swiss firm announced the move as it reported organic growth of 4% at Health Science for 2022.
You may also be interested in...
People On The Move: Appointments At Nestlé, Sanofi, Fimea
A round-up of the latest appointments in Europe's health and wellness markets: Nestlé Health Science promotes Anna Mohl to CEO; Sanofi Consumer Healthcare names Thomas Bosment Romania country head; Fimea reappoints Eija Pelkonen as director general for another five year term.
Nestlé Invests In Microbiome Research As VMS Sales Stumble
Nestlé announced a partnership with APC Microbiome Ireland for product development as it reported lower vitamin, mineral and supplement sales in the first half of 2023.
Nestlé Insists VMS Market Is Picking Up Despite Lower Sales In Q1
Nestle said a slowdown in the US dietary supplements market was to be expected following a strong increase during the pandemic as it reported lower VMS sales in Q1. “We are starting to see signs of market growth picking up again,” CFO François-Xavier Roger told the Swiss firm’s earnings call.